Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP

Journal of Bioscience and Bioengineering

Volumn 110, Issue 2, 2010, Pages 250-253

  Nakajima, Hiroo ^a   Mizuta, Naruhiko ^b   Sakaguchi, Koichi ^b   Fujiwara, Ikuya ^b   Yoshimori, Atsushi ^c   Magae, Junji ^d   Tanuma, Sei ichi ^c  

^a Tsujigiwa Daigo Clinic   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d CENTRAL RESEARCH INSTITUTE OF ELECTRIC POWER INDUSTRY   (Japan)

Author keywords

Apoptosis; Breast cancer; HER2; HRAP; Paclitaxel; Pertuzumab

Indexed keywords

APOPTOSIS; BREAST CANCER; EXTRACELLULAR DOMAINS; HUMAN BREAST CANCER CELLS; INDUCED APOPTOSIS; INTERACTING SITES; PACLITAXEL; SIGNAL TRANSDUCTION PATHWAYS;

AMINO ACIDS; BIOMIMETICS; CELL CULTURE; PHOSPHATASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CELL DEATH;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 REACTIVE ANTAGONISTIC PEPTIDE; PACLITAXEL; PENTAPEPTIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CYTOTOXICITY; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMIMETIC MATERIALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; HUMANS; OLIGOPEPTIDES; PACLITAXEL; PHOSPHORYLATION; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 77954313321     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2010.02.007     Document Type: Article

References (23)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A, McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification on the HER-2/neu oncogene. Science 1987, 235:177-182.
2. Crowder R.J., Lombardi D.P., Ellis M.J. Successful targeting of ErbB2 receptors-is PTEN the key. Cancer Cell 2004, 6:103-104.
3. Zhang H., Richter M., Greene M.I. Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Cancer Biol. Ther. 2003, 2:S122-S126.
4. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357:39-51.
5. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograft. Cancer Res. 1998, 58:2825-2831.
6. Lee S., Yang W., Lan K.H., Sellappan S., Klos K., Hortobagyi G., Hung M.C., Yu D. Enhanced sensitization to Taxol-induced apoptosis by Herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res. 2002, 62:5703-5710.
7. Liang K., Lu Y., Jin W., Ang K.K., Milas L., Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol. Cancer Ther. 2003, 2:1113-1120.
8. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., other 3 authors PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
9. Agus D.A., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., Scher H.I., Sliwkowski M.X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
10. Kallioniemi O.P., Holli K., Visakorpi T., Koivula T., Helin H.H., Isola J.J. Association of c-ErbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int. J. Cancer 1991, 49:650-655.
11. Kirsch D.G., Hochberg F.H. Targeting HER2 in brain metastasis from breast cancer. Clin. Cancer Res. 2003, 9:5435-5439.
12. Grossi M., Ochiai H., Archer G.E., McLendon R.E., Zalutsky M.R., Friedman A.H., Friedman H.S., Bigner D.D., Sampson J.H. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin. Cancer Res. 2003, 9:5514-5520.
13. Nakajima H., Mizuta N., Sakaguchi K., Fujiwara I., Yoshimori A., Takahashi S., Takasawa R., Tanuma S. Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods. Breast Cancer 2008, 15:65-72.
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
15. Gerlier D., Thomasset N. Use of MTT colorimetric assay to measure cell activation. J. Immunol. Methods 1986, 94:57-63.
16. Tewari M., Quan L.T., O'Rourke K., Desnoyers S., Zeng Z., Beidler D.R., Poirier G.G., Salvesen G.S., Dixit V.M. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose)polymerase. Cell 1995, 81:801-809.
17. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
18. Nagata S. Apoptosis by death factor. Cell 1997, 88:355-365.
19. Vazquez F., Ramaswamy S., Nakamura N., Sellers W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 2000, 20:5010-5018.
20. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 1999, 13:2905-2927.
21. Berezov A., Zhang H.T., Greene M.I., Murali R. Disabling ErbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J. Med. Chem. 2001, 44:2565-2574.
22. Park B.W., Zhang H.T., Wu C., Berezov A., Zhang X., Dua R., Wang Q., Kao G., O'Rourke D.M., Greene M.I., Murali R. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 2000, 18:194-198.
23. Fantin V.R., Berardi M.J., Babbe H., Michelman M.V., Manning C.M., Leder P. A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. Cancer Res. 2005, 65:6891-6900.